January 15, 2021

BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai – 400 001
Scrip code: 532531

The National Stock Exchange of India Limited
Exchange Plaza, Bandra-Kurla Complex
Bandra (E) Mumbai - 400 051
Scrip code: STAR

Dear Madam/ Sir,

Sub: Press Release

Please find attached Press Release issued by the Company titled:

“Strides receives USFDA approval for Emtricitabine and Tenofovir Disoproxil Fumarate Tablets”

Thanks & Regards,

For Strides Pharma Science Limited,

Manjula Ramamurthy
Company Secretary

Encl. As above
Strides receives USFDA approval for Emtricitabine and Tenofovir Disoproxil Fumarate Tablets

Product approval under the para IV route

Bengaluru, January 15, 2021 – Strides Pharma Science Limited (Strides) today announced that its step-down wholly owned subsidiary, Strides Pharma Global Pte. Limited, Singapore, has received approval for Emtricitabine and Tenofovir Disoproxil Fumarate Tablets, 200 mg/300 mg from the United States Food & Drug Administration (USFDA). The product is bioequivalent and therapeutically equivalent to the Reference Listed Drug (RLD), Truvada Tablets, 200 mg/300 mg, of Gilead Sciences.

According to IQVIA MAT November 2020 data, the US market for Emtricitabine and Tenofovir Disoproxil Fumarate Tablets, 200 mg/300 mg is approximately US$ 2.4 Bn. The product will be manufactured at the company’s facility at Bengaluru and will be marketed by Strides Pharma Inc. in the US market.

The company has 127 cumulative ANDA filings with USFDA of which 95 ANDAs have been approved and 32 are pending approval.

About Emtricitabine and Tenofovir Disoproxil Fumarate Tablets
Emtricitabine and tenofovir belong to class of medications called nucleoside and nucleotide reverse transcriptase inhibitors. The combination of Emtricitabine and Tenofovir slows down the spread of HIV in the body and is used along with other medications to treat HIV in adults and children.

About Strides
Strides, listed on the BSE Limited (532531) and National Stock Exchange of India Limited (STAR), is a global pharmaceutical company headquartered in Bengaluru, India. The Company mainly operates in the regulated markets and has an “in Africa for Africa” strategy along with an institutional business to service donor-funded markets. The Company’s global manufacturing sites are located in India (Chennai, Puducherry and two locations in Bengaluru), Singapore, Italy (Milan), Kenya (Nairobi) and the United States (Florida). The Company focusses on “difficult to manufacture” products that are sold in over 100 countries. Additional information is available at the Company’s website at www.strides.com

For further information, please contact:

<table>
<thead>
<tr>
<th>Strides</th>
<th>Corporate Communication</th>
</tr>
</thead>
<tbody>
<tr>
<td>Badree Komandur Executive Director - Finance</td>
<td>Usha Iyer: +91 99874 44106</td>
</tr>
<tr>
<td>+91 80 6784 0747</td>
<td>Email: <a href="mailto:usha.iyer@strides.com">usha.iyer@strides.com</a></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Investor Relations</th>
<th>PR Consultancy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sandeep Baid: +91 80 6784 0791</td>
<td>Fortuna PR</td>
</tr>
<tr>
<td>Email: <a href="mailto:Sandeeb.baid@strides.com">Sandeeb.baid@strides.com</a></td>
<td>K Srinivas Reddy: +91 90005 27213</td>
</tr>
<tr>
<td></td>
<td>Email: <a href="mailto:srinivas@fortunapr.com">srinivas@fortunapr.com</a></td>
</tr>
</tbody>
</table>

|                            | K Priya: +91 95354 25418 |
|                            | Email: priya@fortunapr.com |